This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CDH17 · Western blot design guide
CDH17 Western Blot Planning Guide
Plan a CDH17 Western blot around the catalog-observed 92.2 kDa band, image-backed PA2200 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
CDH17 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 92.2 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Colon | |
| Negative control | Adipose tissue |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 92.2 kDa |
| ⓘ | Localization | Cell membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Section 1
Real Curated CDH17 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Appendix |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PA2200 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected CDH17 Western Blot Band Size?
Use the product-observed 92.2 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 92.2 kDa | Matches the authoritative product WB observation. |
| 92.2 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected CDH17 appearancePlan around 92.2 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 92.2 kDa; use this as the primary experimental expectation. |
| Calculated mass | 92.2 kDa from UniProt Q12864; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PA2200. |
| Situation | Likely cause | Next action |
|---|---|---|
| 92.2 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing CDH17 band
PA2200 · CDH17
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for CDH17 Western blot
🧪Use Colon as the first positive-control candidate and Adipose tissue as the HPA Not detected negative candidate.
Positive control: Colon (High)
Negative control: Adipose tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for CDH17
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Colon | Reported tissue cells | High | Protein (HPA) | HPA → |
| Small intestine | Reported tissue cells | High | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | High | Protein (HPA) | HPA → |
| Duodenum | Reported tissue cells | High | Protein (HPA) | HPA → |
Section 3
Advanced CDH17 Western Blot Tips
Deeper troubleshooting and optimisation questions for CDH17, answered from its protein features.
Which band should guide the blot?
Use 92.2 kDa, the observation attached to the authoritative PA2200 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 92.2 kDa expectation.
Which positive control should I start with?
Start with Colon, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Adipose tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for CDH17 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PA2200 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
CDH17 Western Blot Reagents
Human-reactive CDH17 Western blot reagents with authoritative product imagery.
Real WB data
Anti-LI-Cadherin-17 CDH17-Antibody Picoband®
Cat # PA2200
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q12864
- Human Protein Atlas — CDH17
- PA2200 product record
- PMC12217925 — Loss of cadherin 17 downregulates LGR5 expression, stem cell properties and drug resistance in metastatic colorectal cancer cells (Cell death & disease, 2025)
- PMC13398008 — A Novel Anti-Cadherin-17 Monoclonal Antibody, Ca(17)Mab-5, for Multiple Applications (Antibodies (Basel, Switzerland), 2026)
- PMC10807196 — A complex of cadherin 17 with desmocollin 1 and p120-catenin regulates colorectal cancer migration and invasion according to the cell phenotype (Journal of experimental & clinical cancer research : CR, 2024)